Predict your next investment

HEALTHCARE
ocularispharma.com

See what CB Insights has to offer

Stage

Other Investors | Alive

About Ocularis Pharma

Night Vision Complaints, which range from patient dissatisfaction to complete impairment due to glare, halos, starbursts, ghosting patterns, poor contrast and poor depth perception in dim light, have been recognized for many years, but have only received significant attention in the past decade, as the advent of intraocular lens implants and refractive surgery has produced significant numbers of patients who experience acute and chronic NVCs post-operatively. There is no medication on the market today indicated for the treatment of Night Vision Complaints.To address the problem of NVCs due to light scatter, Ocularis has patented the use of an entire class of molecules that have been demonstrated to inhibit pupil dilation in dim light. The lead product, Nyxol Eye Drops, has been shown to be safe and effective in reducing pupil size in a Phase I clinical trial. Furthermore, Ocularis has successfully tested the drug in a Phase I/II clinical study demonstrating statistically and clinically significant improvement in low contrast visual acuity in dim light. A Phase II clinical study in patients with moderate to severe night vision complaints is underway.Management expects to develop Nyxol Eye Drops within four years with a broad indication that will permit its use in the widest possible range of patient groups.

Ocularis Pharma Headquarter Location

2436 S 6th Avenue

North Riverside, Illinois, 60546,

United States

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Ocularis Pharma

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Ocularis Pharma is included in 1 Expert Collection, including Pharma Supply Chain.

P

Pharma Supply Chain

1,258 items

Ocularis Pharma Patents

Ocularis Pharma has filed 9 patents.

The 3 most popular patent topics include:

  • Beta blockers
  • Ophthalmology
  • Stereoscopy
patents chart

Application Date

Grant Date

Title

Related Topics

Status

9/25/2017

5/11/2021

Ophthalmology, Vision, Beta blockers, Diseases of the eye and adnexa, Stereoscopy

Grant

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

Application Date

9/25/2017

00/00/0000

00/00/0000

00/00/0000

00/00/0000

Grant Date

5/11/2021

00/00/0000

00/00/0000

00/00/0000

00/00/0000

Title

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Related Topics

Ophthalmology, Vision, Beta blockers, Diseases of the eye and adnexa, Stereoscopy

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Status

Grant

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.